To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
All releases
English
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology
Initiator Pharma A/S, a clinical-stage biotech company, today announced that an article titled “A novel reuptake inhibitor induces erection by increasing central dopamine and peripheral nitric oxide release” was published in the prestigious peer-reviewed scientific journal British Journal of Pharmacology.
MAC Clinical Research converts its receivable into shares in Initiator Pharma
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at MAC Clinical Research Finance Ltd (“MAC”) in connection with MAC’s conversion notice regarding conversion of outstanding receivable on February 20th.
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a directed buyback of shares in order to sell shares to the board of directors under the LTI2021-program.
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the company will expand the position of the company to a broader Sexual Health Franchise including both male Erectile Dysfunction (ED) and Female Sexual Dysfunction (FSD) indications. Initiator Pharma will be in San Francisco to present the company at business and investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference January 8 to 11.